<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Drug id="75324" name="tenofovir alafenamide + emtricitabine + cobicistat + elvitegravir (FDC, HIV), Gilead/ Japan Tobacco"><HDS>Launched</HDS><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><Actions><Action id="7418" type="primary">Cytochrome P450 3 inhibitor</Action><Action id="1832" type="primary">Nucleoside reverse transcriptase inhibitor</Action><Action id="7588" type="primary">HIV-1 integrase inhibitor</Action><Action id="1016" type="primary">HIV-1 reverse transcriptase inhibitor</Action><Action id="1671" type="primary">HIV integrase inhibitor</Action><Action id="768" type="primary">HIV-1 protease inhibitor</Action><Action id="991" type="secondary">Antiviral</Action><Action id="747" type="secondary">HIV replication inhibitor</Action></Actions><Indications><Indication id="159" type="primary">HIV-1 infection</Indication></Indications><Entities><Entity>Chemical</Entity></Entities><OriginatorCompany id="16450">Gilead Sciences Inc</OriginatorCompany></Drug>